Skip to content

The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes

Infertility | Infertility Unexplained | Infertility of Uterine Origin |...

The goal of this clinical trial is to test the effect of granulocyte colony-stimulating factor (G-CSF, A.K.A. Filgrastim) in infertility patients undergoing in vitro fertilization (IVF) treatment. The main question it aims to answer is:

Can in vitro fertilization-embryo transfer (IVF-ET) outcomes be improved by supplementing the transfer media with Granulocyte colony-stimulating factor (GCSF)?

Participants will undergo their embryo transfer as per the normal clinic protocol but will be randomized to either receive the standard embryo transfer media or the GCSG-supplemented transfer media.

Researchers will compare the GCSF and standard transfer media groups to see if clinical outcomes are improved (i.e., implantation rate, pregnancy, clinical pregnancy rate, live birth rate).

null

Conditions de participation

  • Sexe:

    FEMALE

  • Âges admissibles:

    18 to 38

Critères de participation

Inclusion Criteria:

* Recruited subjects will either be undergoing a fresh IVF-ET cycle in which the embryo(s) generated from the initial treatment cycle are transferred during that same cycle (i.e., on day 5 or 6 post-egg retrieval) or an FET cycle in which the embryo(s) transferred were generated in a previous IVF cycle and were cryopreserved for subsequent warming and transfer.

Exclusion Criteria:

* Patients with uterine factor or severe male factor infertility will be excluded.
* Patients who have had previous IVF failures will be excluded.

Lieu de l'étude

Newlife Fertility Centre
Newlife Fertility Centre
Mississauga, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
Newlife Fertility Centre
Participants recherchés
Plus d'informations
ID de l'étude: NCT06174298